BBM Workgroup Presentation at Alzheimer’s Association International Conference 2023

CEOi held a BBM Workgroup meeting at AAIC 2023. Workstream leads, Suzanne Schindler, Michelle Mielke, and Chi Udeh-Momoh presented progress on the Workgroup’s outputs to prepare for widespread adoption of blood-based biomarkers into clinical practice. The presentation was moderated by John Dwyer, BBM Workgroup Steering Committee member.

Previous
Previous

Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape

Next
Next

The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease